Diffuse large B cell lymphoma: prognostic factors in the rituximab era = Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab

Diffuse large B cell lymphoma: prognostic factors in the rituximab era = Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab

Introduction: The inclusion of rituximab for treatment of diffuse large B cell lymphoma (DLBCL) generated the need to re-assess the conventionally employed prognostic factors and to explore others that could be useful for prognostic purposes. Objective: To describe the most important clinical, he...

Full description

Bibliographic Details
Main Authors: Natalia María Guevara Arismendy, Patricia Elena Jaramillo Arbeláez, Lina María Gaviria Jaramillo
Format: Article
Language:Spanish
Published: Universidad de Antioquia 2013-07-01
Series:Iatreia
Subjects:
Antígenos CD5
Beta 2-Microglobulina
Linfoma de Células B Grandes Difuso
Antigens
CD5
Bone Marrow
Large B-cell Diffuse Lymphoma
Migroglobuline beta-2
Online Access:http://www.iatreia.udea.edu.co/index.php/iatreia/article/view/13680/13597

Internet

http://www.iatreia.udea.edu.co/index.php/iatreia/article/view/13680/13597

Similar Items